Clinical Trials

HER2 Positive Breast Cancer

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06136897 2026-04-13

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

35 enrolled 10 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06663787 2026-04-13

HER2 CR

Active not recruiting

50 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

68 enrolled

Breast Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

Phase 2/3 Not yet recruiting

HER2-positive Gastric Cancer

NCT07413939 2026-04-09

BREnnA

650 enrolled

HER2-positive Breast Cancer

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Phase 3 Not yet recruiting

Resectable HER2-positive Breast Cancer

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

596 enrolled

Phase 3 Active not recruiting

HER2-positive Breast Cancer

NCT05132582 2026-04-07

HER2CLIMB-05

654 enrolled

Breast Neoplasms

NCT05253651 2026-04-07

MOUNTAINEER-03

400 enrolled

Colorectal Neoplasms

NCT06876714 2026-04-07

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

1,524 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

113 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

1,000 enrolled

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04309578 2026-04-03

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Phase 2 Completed

28 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT05408845 2026-04-03

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Breast Neoplasms

NCT02693535 2026-04-02

TAPUR

Phase 3 Active not recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04208178 2026-04-02

EPIK-B2

19 enrolled

Advanced HER2+Breast Cancer

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05378464 2026-04-01

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

28 enrolled

Breast Neoplasms

NCT05515796 2026-04-01

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Phase 2 Completed

189 enrolled

Rectal Neoplasms, Stomach Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

776 enrolled

Tumor-Agnostic

Neoplasms

NCT03297606 2026-03-27

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06178445 2026-03-27

TRAP-BTC

24 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

544 enrolled

HER2-positive Breast Cancer

NCT04158258 2026-03-24

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active not recruiting

2,907 enrolled

Breast Neoplasms

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

60 enrolled

Breast Neoplasms

NCT02654119 2026-03-23

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Phase 2 Completed

20 enrolled 12 charts

Breast Neoplasms

NCT04266249 2026-03-23

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT05143970 2026-03-20

CHANCES

BreastGastrointestinalGynecologicThoracic

27 enrolled

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05187182 2026-03-18

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

42 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT05323955 2026-03-17

BRIDGET

48 enrolled

CNS

Brain Neoplasms

NCT01613482 2026-03-16

TSARINE

Phase 3 Terminated

13 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04253561 2026-03-16

IPATHER

Phase 1 Completed

17 enrolled

Breast Neoplasms

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

726 enrolled

Stomach Neoplasms

NCT01042379 2026-03-13

I-SPY